Sanofi’s Rezurock Secures Marketing Approval in China for Chronic Graft-vs-Host Disease
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that its drug Rezurock (belumosudil), the world’s...
NASDAQ: SNY
Sanofi Abandons MZE001 Licensing Deal Following FTC Intervention Over Pompe Disease Monopoly Concerns
Sanofi (NASDAQ: SNY) has withdrawn from an agreement announced earlier this year to in-license the...
Sanofi Partners with Minapharm for Local Production of Anticoagulant Clexane in Egypt
Sanofi (NASDAQ: SNY) has entered into a partnership with Egyptian biotechnology company Minapharm to locally...
Sanofi Eyes Blockbuster Potential with 12 Pipeline Assets, Projects EUR 10 Billion in Annual Sales by 2030
Sanofi (NASDAQ: SNY) this week outlined its growth potential for the 2024 to 2025 period,...
Dupixent Trial Success Reinforces Potential in Moderate-to-Severe COPD Treatment
Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) have announced that a late-stage replicate trial...
Sanofi Regains Exclusive Rights to Rezurock in China, Terminating Agreement with BioNova and BK Pharmaceuticals
BioNova Pharmaceuticals, a Shanghai-based oncology-focused biopharmaceutical company founded in 2018, and Sanofi (NASDAQ: SNY), a...
Sanofi SA Reports Q3 2023 Financials with Focus on R&D and Dupixent Growth
French pharmaceutical giant Sanofi SA (NASDAQ: SNY) released its Q3 2023 financial results, reporting a...
Sanofi Enters Collaboration with Teva for IBD Drug TEV’574 Development
Sanofi (NASDAQ: SNY) has entered into a collaboration agreement with Teva (NYSE: TEVA) for the...
Sanofi’s Nexviazyme Approved in China as Enzyme Replacement Therapy for Pompe Disease
Sanofi’s (NASDAQ: SNY) next-generation enzyme replacement therapy (ERT), Nexviazyme (avalglucosidase alfa), has received marketing approval...
Janssen and Sanofi Partner for Development of First-in-Class E. coli Vaccine
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has entered into a strategic...
Sanofi’s Altuviiio Receives Marketing Approval from Japan’s MHLW for Hemophilia A Treatment
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that it has received marketing approval from...
Sanofi’s Dupixent Secures NMPA Approval for Pruritigo Nodosa Treatment in China
France-based pharmaceutical company Sanofi (NASDAQ: SNY) has announced that it has received another indication approval...
Pharmanovia Bolsters Neurology Portfolio with Acquisition of Sanofi’s CNS Products
UK-based healthcare company Pharmanovia has announced the expansion of its neurology portfolio through the strategic...
Sanofi Announces Management Restructuring with New Leadership Roles in China
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced a significant restructuring of its management structure...
Eli Lilly’s Retevmo Meets Primary Endpoint in Phase III Trial for RET-mutant Medullary Thyroid Cancer
Eli Lilly (NYSE: LLY) has announced that its Phase III trial for the RET kinase...
Sanofi Misses Out on Acquiring Reata Pharmaceuticals to Biogen in USD 7.3 Billion Deal
Media outlet Bloomberg reported today that France-based Sanofi (NASDAQ: SNY) lost a bidding war to...
Sanofi to Boost CHC Unit with Full Acquisition of US Health Brand Qunol
France-based pharmaceutical giant Sanofi (NASDAQ: SNY) has revealed that it has signed an agreement to...
Sanofi Reports 3.3% YOY Sales Growth in Q2 2023, Driven by Vaccines and Dupixent
France-based Sanofi (NASDAQ: SNY) has released its financial results for the second quarter of 2023,...
Sanofi and AstraZeneca Receive FDA Approval for RSV Prevention Treatment Beyfortus
France-based Sanofi (NASDAQ: SNY) has announced that it, along with AstraZeneca (AZ; NASDAQ: AZN), has...
Sanofi’s Commitment to China: Expansion, Digital Innovation, and Local R&D
Wayne Shi, president of France-based Sanofi’s (NASDAQ: SNY) Greater China business, has been discussing the...